Tell us about your product, market, and timeline — our specialists will design a testing programme that fits.
Our scientific team will help you identify the right tests, methods, and accreditations for your product or sample.
The Bangalore Pharmaceutical Testing Laboratory at Yeshwanthpur provides NABL-accredited pharmaceutical testing under ISO/IEC 17025:2017 (Certificate TC-5496) for South India pharmaceutical and biotech manufacturers. The 13-entry pharmaceutical scope under NABL covers stability, assay, dissolution, and microbiological testing, supported by WHO Prequalified and US FDA-inspected analytical capability.
NABL Certificate: NABL TC-5496
Validity: Valid until March 2026 (renewal in progress)
Phone: +91 74281 16100
Email: [email protected]
Six pharmaceutical testing categories confirmed in the Bangalore NABL pharmaceutical scope (TC-5496, 13 entries).
Real-time and accelerated stability studies under ICH-aligned conditions for finished pharmaceutical formulations.
HPLC and titrimetric assay of active pharmaceutical ingredients in finished dosage forms against pharmacopoeial monographs.
USP apparatus dissolution testing for solid and semi-solid dosage forms under NABL-accredited conditions.
Microbial limits, total plate count, yeast and mould, and pathogen testing for non-sterile pharmaceutical products per USP and IP.
Identity, purity, and pharmacopoeial conformity testing for incoming APIs and excipients within the accredited scope.
Batch release testing for finished pharmaceutical formulations against established specifications and pharmacopoeial limits.
Scope note: For nitrosamine impurity testing (ICH M7), endotoxin testing (LAL / rFC), advanced impurity profiling, and method development and validation, route clients to the Delhi (NABL TC-7375) or Manesar (NABL TC-15532) facilities.
Three reasons pharmaceutical and biotech companies across Karnataka and South India choose the Bangalore lab.
Reports accepted for international regulatory submissions, WHO PQ tender packages, UN agency procurement, and Global Fund workflows.
US FDA-inspected pharmaceutical testing facility. Reports accepted by US market buyers, contract manufacturers, and US importers.
Ideal for pharmaceutical companies in Karnataka and South India requiring locally issued, internationally accepted analytical certificates.
Four steps from initial enquiry to digital report. Standard TAT 5 to 7 working days. Express testing available.
Call your single point of contact at +91 74281 16100 to confirm the test scope, applicable pharmacopoeial standard, and sample submission details.
Drop the sample at the Yeshwanthpur address or send by pre-approved courier. Each sample is bar coded on receipt and registered in YLIMS.
Testing is conducted under NABL-accredited conditions (TC-5496) with in-process QA checks against the applicable pharmacopoeial standard.
The digital report is issued and accessible via YLIMS. Standard TAT is 5 to 7 working days. Express testing available.
Three credentials held at the Bangalore facility supporting pharmaceutical testing.
ISO/IEC 17025:2017, Valid Mar 2026 (renewal in progress)
WHO PQ recognition for analytical testing scope
US FDA inspected pharmaceutical testing facility
See the full national pharmaceutical testing scope, or return to the Bangalore lab hub.
National pharmaceutical testing service page covering nitrosamine workflows, endotoxin testing, impurity profiling, and method development at Delhi and Manesar.
Go to national service page →Bangalore lab overview covering food, pharmaceutical, water, cosmetics, microbiological, and sensory analysis scope.
Back to Bangalore lab hub →NABL TC-5496 accredited pharmaceutical testing. WHO Prequalified and US FDA-inspected facility. Standard TAT 5 to 7 working days. Express options available.
Download a practical testing guide tailored to your industry — checklists, parameters, and regulatory tips in one place.
Download Guide Request a Quote InsteadNo thanks, I'll keep browsing